Microbot Medical Inc. has announced that it recently received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System. This regulatory approval allows the company to move forward with its commercial launch plans, including exhibiting the system at the upcoming Symposium on Clinical Interventional Oncology. The clearance was granted solely to Microbot Medical Inc., and the company has also completed recruitment of its commercial leadership team in preparation for a limited market launch later this quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microbot Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546625-en) on October 16, 2025, and is solely responsible for the information contained therein.
Comments